Digital Therapeutic Leaders Dthera Sciences’ and Click Therapeutics’ Executives to act as Co-Chairs of Second Digital Therapeutics Summit
SAN DIEGO, CA / ACCESSWIRE / September 25, 2018 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that its CEO, Edward Cox, has been selected to co-chair the Digital Therapeutics and Digital Medicine Summit (DTxDM) alongside Joel Sangerman, Chief Commercial Officer of Click Therapeutics, a company developing software as prescription medical treatments.
″I am honored to again co-chair this event, alongside Joel, and to follow-on from last spring’s successful DTxDM event,″ said Edward Cox, CEO of Dthera Sciences. ″It is remarkable to see how far Digital Therapeutics has come in the last 6 months, and it is exciting for effectively all of the leading DTx companies to again to be in the same room at the same time collaborating, sharing knowledge, and collectively shaping the future of our dynamic new sector.″
The summit, taking place September 25th-26th, is aimed at defining the current and future landscape of the rapidly emerging Digital Therapeutics industry. In addition to Mr. Cox and Mr. Sangerman, a number of other notable speakers will be presenting including:
Bakul Patel, Associate Centre Director for Digital Health, U.S. Food and Drug Administration
Brandon Masteron, CEO, 2Morrow, Inc.
Pierre Larent, CEO, Voluntis
Eddie Martucci, CEO, Akili Interactive Labs
Kevin McRaith, CEO, WellDoc
Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis
Alex Waldron, CCO, Pear Therapeutics
Brent Vaughn, CEO, Cognoa
Adam Kaufman, CEO, Canary Health
Swatee Surve, CEO, Litesprite
Peter Hames, CEO, Big Health
Debra Reisenthel, CEO, Palo Alto Health Sciences
Bozidar Jovicevic, VP, Global Head of Digital Medicine, Sanofi
Melinda Decker, Head, Oncology & Immuno-Oncology Pharmaceuticals, AstraZeneca
About the Digital Therapeutics and Digital Medicine Summit, DTxDM
The Digital Therapeutics & Digital Medicine Summit (a Grey Green Media event, www.greygreenmedia.com ) provides the industry’s first dedicated platform for digital therapeutic/medicine companies, pharma, investors and solution-providers to come together to advance this next generation of validated digital healthcare. Constructed with industry leaders, the inaugural DTx East (September 25th-26th, Boston, MA) will be showcasing the latest advancements, hosting crucial discussions and providing unprecedented networking opportunities for the pioneers and future adopters of digital therapeutics and digital medicine. The next event in the series is DTx West, which takes place in February in San Mateo, CA.
About Dthera Sciences
Dthera Sciences (OTCQB: DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego-based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. Dthera has two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation and dementia; and DTHR-ALZ, a development-stage product that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer’s disease.
About Digital Therapeutics
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors’ and nurses’ care, changing patient behavior, and most importantly, reducing cost of care.
Company Contact Geno Kostikov, Corporate Development
Media Relations Joice Truban Curry, Publicist
c3 Communications, Inc.
Investor Relations Marek Ciszewski, J.D., Managing Director, Head of Life Sciences
Liolios Group, Inc.
SOURCE: Dthera Sciences